United States News Beep
  • News Beep
  • Breaking News
  • Business
  • Entertainment
  • Health
  • Science
  • Sports
  • Technology
United States News Beep
United States News Beep
  • News Beep
  • Breaking News
  • Business
  • Entertainment
  • Health
  • Science
  • Sports
  • Technology

Browsing Tag

novartis

11 posts
UUnited States
Novartis agrees to acquire a pan-mutant-selective PI3Kα inhibitor, strengthening its breast cancer pipeline
Read More

Novartis announces expansion of community health programs to close gaps in heart disease and cancer care, targeting more than 30 countries by 2030

  • April 9, 2026
Strengthens three community health models spanning community‑embedded care, earlier intervention and data‑driven population healthScales program footprint from 11…
BBusiness
Novartis agrees to acquire a pan-mutant-selective PI3Kα inhibitor, strengthening its breast cancer pipeline
Read More

Novartis agrees to acquire Excellergy, Inc., building on allergy leadership with next-generation anti-IgE innovation

  • March 27, 2026
– Proposed acquisition strengthens Novartis immunology strategy in food allergy and other IgE-driven diseases   – Lead asset Exl-111 builds…
BBusiness
Novartis agrees to acquire a pan-mutant-selective PI3Kα inhibitor, strengthening its breast cancer pipeline
Read More

Novartis agrees to acquire a pan-mutant-selective PI3Kα inhibitor, strengthening its breast cancer pipeline

  • March 20, 2026
Proposed acquisition supports the Novartis oncology strategy in hormone receptor positive, human epidermal growth factor receptor two-negative (HR+/HER2-)…
MMedication
Novartis and US government reach agreement on lowering drug prices in the US
Read More

Novartis remibrutinib first therapy to achieve Phase III primary endpoint in chronic inducible urticaria (CIndU)

  • February 21, 2026
Statistically significant and clinically meaningful results seen in RemIND trial with complete responses achieved in 3 CIndU types1Remibrutinib,…
HHealth care
Novartis and US government reach agreement on lowering drug prices in the US
Read More

Novartis and US government reach agreement on lowering drug prices in the US

  • December 19, 2025
Novartis agrees to take actions aimed at meeting US Administration priorities for drug pricingAdditional Novartis medicines will be…
UUnited States
Novartis to acquire Tourmaline Bio, complementing cardiovascular pipeline with pacibekitug for the treatment of atherosclerotic cardiovascular disease (ASCVD)
Read More

Novartis and US government reach agreement on lowering drug prices in the US

  • December 19, 2025
Novartis agrees to take actions aimed at meeting US Administration priorities for drug pricingAdditional Novartis medicines will be…
HHealth
Novartis to acquire Tourmaline Bio, complementing cardiovascular pipeline with pacibekitug for the treatment of atherosclerotic cardiovascular disease (ASCVD)
Read More

Novartis Phase III trial for next-generation malaria treatment KLU156 (GanLum) meets primary endpoint, with potential to combat antimalarial resistance

  • November 13, 2025
Phase III trial for KLU156 (ganaplacide/lumefantrine, or GanLum), meets primary endpoint of non-inferiority to standard of care Coartem®…
MMarkets
Mexico Biologicals Market to Worth Over US$ 2,268.76 Million by 2033
Read More

Radiopharmaceuticals Market to Reach US$ 13.4 Billion by 2033

  • October 23, 2025
AstuteAnalytica India Pvt. Ltd. Surging multibillion dollar acquisitions and a pipeline of innovative therapies define the current landscape.…
GGenetics
One in four Indians faces silent genetic threat to heart health, shows study
Read More

One in four Indians faces silent genetic threat to heart health, shows study

  • September 24, 2025
In the Asia Pacific and Middle East region, two in three individuals (66%) skip routine heart tests, while…
BBusiness
Novartis to acquire Tourmaline Bio, complementing cardiovascular pipeline with pacibekitug for the treatment of atherosclerotic cardiovascular disease (ASCVD)
Read More

Novartis to acquire Tourmaline Bio, complementing cardiovascular pipeline with pacibekitug for the treatment of atherosclerotic cardiovascular disease (ASCVD)

  • September 10, 2025
  Tourmaline Bio is a clinical-stage biopharmaceutical company developing pacibekitug, an anti-IL-6 mAb, as a treatment option for…
BBusiness
Novartis announces both ianalumab Phase III clinical trials met primary endpoint in patients with Sjögren’s disease  
Read More

Novartis announces both ianalumab Phase III clinical trials met primary endpoint in patients with Sjögren’s disease  

  • August 12, 2025
Ad hoc announcement pursuant to Art. 53 LR NEPTUNUS-1 and NEPTUNUS-2 are the first ever global phase III…
United States News Beep
www.newsbeep.com